Skip to main content
. 2019 Apr 23;11(4):572. doi: 10.3390/cancers11040572

Figure 9.

Figure 9

rTNF-induced dysfunction of GJIC was further enhanced in the presence of LMW PAHs. (a) A SL/DT assay was used to measure GJIC 4 h following treatment with rTNF (1 ng/mL), LMW PAH mixture (40 µM; 1:1 ratio of 1-methylanthracene and fluoranthene), or combinations of both rTNF and PAH mixture. * p < 0.05 treatment at both time points compared to control. * p < 0.05 treatment at both time points compared to control; + p < 0.05 for PAH or rTNF plus PAH (40 μM) treatment. (b) A SL/DT assay was used to measure GJIC 24 h following treatment with rTNF (1 ng/mL), LMW PAH mixture (8 or 15 μM; 1:1 ratio of 1-methylanthracene and fluoranthene), or combinations of both rTNF at either the low (8 μM) or high (15 μM) dose of LMW PAHs. * p < 0.05 treatment at both time points compared to control; + p < 0.05 rTNF treatment at 24 h compared to PAH or the combination of PAH plus rTNF (15 μM) at 24 h; ** p < 0.05 rTNF plus PAH (15 μM) treatment at compared to PAH (15 μM) at 4 h; *** p < 0.05 PAH plus rTNF (8 μM) at 24 h treatment compared to rTNF or PAH (8 μM) at 24 h. Experiments repeated 3 times with an n = 3 per treatment per experiment. (c) Representative images of the experiment depicted in (b). rTNF, recombinant TNF; PAH indicates the LMW PAH mixture described above. Magnification 100×.